• Active, not recruiting

NCT03716856: Phase 1 - CAR-BCMA T in Patients With Refractory or Relapsed Multiple - Chinese study

Updated: May 28


NCT03716856: Phase 1 - Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma


A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR-BCMA T cells in patients with BCMA-positive refractory or relapsed multiple myeloma.


Sponsor

First Affiliated Hospital of Zhejiang University


Collaborator

CARsgen Therapeutics Co., Ltd.

 

ClinicalTrials.gov Identifier: NCT03716856


Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma

First Posted : October 23, 2018

Click here for details on Clinicaltrials.gov

 

CART - BCMA : National Cancer Institute


Genetic: CAR-BCMA T cells

Drug: Fludarabine

Drug: Cyclophosphamide

 

703.Adoptive Immunotherapy: Mechanisms and New Approaches| November 13, 2019

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

https://doi.org/10.1182/blood-2019-126104

 

Location

China, Zhejiang

China, ZhejiangFirst Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, China, 310006,








Posts Archive